ReviewJournal of the American Heart Association2021
Coronavirus Disease 2019-Associated Thrombosis and Coagulopathy: Review of the Pathophysiological Characteristics and Implications for Antithrombotic Management.
Review in Journal of the American Heart Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
96 citing papers in PubMed, 1 synthesis or guideline pooled it, 187 citations in OpenAlex.
- Prophylactic anticoagulants for non-hospitalised people with COVID-19.The Cochrane database of systematic reviews · 2023Pooled it
- Utility of plasma MicroRNA profiling as diagnostic biomarker in immune system activation and inflammation and early predictor of severity in patients with COVID-19.Scientific reports · 2025Article
- Machine learning identifies clinical and sociodemographic factors contributing to post-COVID hospitalization and cardiovascular risk in patients with peripheral artery disease.Scientific reports · 2025Article
- SARS-CoV-2 infection induces pro-fibrotic and pro-thrombotic foam cell formation.Nature microbiology · 2025Article
- Scoping review about pathogenesis, risk factors, and treatment of venous and arterial thrombosis in coronavirus infection.Frontiers in cardiovascular medicine · 2025Review
- Article
- Soluble platelet selectin and platelets in COVID-19: a multifaceted connection.Annals of medicine and surgery (2012) · 2024Review
- Blood perfusion with polymyxin B immobilized columns in patients with COVID-19 requiring oxygen therapy.Scientific reports · 2024Article
- Spontaneous Coronary Artery Dissection and COVID-19: A Review of the Literature.Life (Basel, Switzerland) · 2024Review
- Review
- Simultaneous Double-Vessel Coronary Thrombosis with Sudden Cardiac Arrest as the First Manifestation of COVID-19.Medicina (Kaunas, Lithuania) · 2023Article
- Cerebral venous sinus thrombosis related to SARS-CoV-2 infection in a pediatric patient: A case report.Radiology case reports · 2023Article
- Association of Serum Complement C3 Levels with Severity and Mortality in COVID 19.Indian journal of clinical biochemistry : IJCB · 2023Article
- Beyond the Surface: Investigating the Relationship Between Autoimmune Blistering Disorders and Venous Thromboembolism.Journal of the American Heart Association · 2023Article
- Acute Formation of Thrombus on a Left Atrial Appendage Occlusion Device Immediately After Detachment.JACC. Case reports · 2023Article
- Correlation between Hepatocyte Growth Factor (HGF) with D-Dimer and Interleukin-6 as Prognostic Markers of Coagulation and Inflammation in Long COVID-19 Survivors.Current issues in molecular biology · 2023Review
- Long COVID Syndrome: Lesson Learned and Future Implications.Journal of clinical medicine · 2023Article
- The Role of NETosis and Complement Activation in COVID-19-Associated Coagulopathies.Biomedicines · 2023Article
- Galectin-3 as a Marker for Increased Thrombogenicity in COVID-19.International journal of molecular sciences · 2023Article
- Risk of Thrombosis during and after a SARS-CoV-2 Infection: Pathogenesis, Diagnostic Approach, and Management.Hematology reports · 2023Review
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus-2, which has posed a significant threat to global health. Although the infection is frequently asymptomatic or associated with mild symptoms, in a small proportion of patients it can produce an intense inflammatory and prothrombotic state that can lead to acute respiratory distress syndrome, multiple organ failure, and death. Angiotensin-converting enzyme 2, highly expressed in the respiratory system, has been identified as a functional receptor for severe acute respiratory syndrome coronavirus-2. Notably, angiotensin-converting enzyme 2 is also expressed in the cardiovascular system, and there are multiple cardiovascular implications of COVID-19. Cardiovascular risk factors and cardiovascular disease have been associated with severe manifestations and poor prognosis in patients with COVID-19. More important, patients with COVID-19 may have thrombotic and coagulation abnormalities, promoting a hypercoagulable state and resulting in an increased rate of thrombotic and thromboembolic events. This review will describe the pathophysiological characteristics of the cardiovascular involvement following infection by severe acute respiratory syndrome coronavirus-2, with a focus on thrombotic and thromboembolic manifestations and implications for antithrombotic management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.